BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BBIO · as of Mar 31, 2025
Ownership Breakdown
349
Institutional Holders
▲ 39 vs Q4
$6.45B
Total Inst. Value
▲ $1.60B vs Q4
195.86M
Shares Outstanding
freeFloat 86.31%
186.42M
13F Shares Held
▲ 9.73M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BBIO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 22.06M | 11.60% | 11.60% | $762.45B | May 15, 2025 | ▼ 3.07M |
KOHLBERG KRAVIS ROBERTS & CO. L.P. pharmaceutical preparations | 19.26M | 10.13% | 10.13% | $665.85B | May 15, 2025 | ▼ 6.00M |
VANGUARD GROUP INC pharmaceutical preparations | 14.90M | 7.84% | 7.84% | $515.10B | May 9, 2025 | ▼ 177.8K |
BLACKROCK, INC. pharmaceutical preparations | 13.36M | 7.02% | 7.02% | $461.77B | May 2, 2025 | ▼ 352.1K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 7.17M | 3.77% | 3.77% | $251.73B | May 15, 2025 | ▲ 2.26M |
AISLING CAPITAL MANAGEMENT LP pharmaceutical preparations | 6.07M | 3.19% | 3.19% | $209.78B | May 13, 2025 | — held |
STATE STREET CORP pharmaceutical preparations | 5.75M | 3.02% | 3.02% | $198.76B | May 15, 2025 | ▼ 433.0K |
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 5.73M | 3.01% | 3.01% | $198.12B | May 15, 2025 | ▲ 1.54M |
CAPITAL RESEARCH GLOBAL INVESTORS pharmaceutical preparations | 4.67M | 2.45% | 2.45% | $161.35B | May 12, 2025 | ▲ 1.14M |
UBS GROUP AG pharmaceutical preparations | 3.89M | 2.04% | 2.04% | $134.35B | May 13, 2025 | ▼ 115.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+18.12M shares3
New Positions
first time holders17
Decreased
−12.64M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.48M
+18.12M / −12.64M
Net new holders
+13
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BBIO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
5
Buy transactions
35
Sell transactions
0.14
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 2,256 | $67.57 | $152.4K | 267.2K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 6,725 | $68.30 | $459.3K | 260.4K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 5,072 | $69.22 | $351.1K | 255.4K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 11,250 | $70.48 | $792.9K | 244.1K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 21, 2026 | Sale | 800 | $70.92 | $56.7K | 243.3K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 16, 2026 | Tax Withhold | 22,781 | $66.13 | $1.51M | 372.8K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 18, 2026 | Sale | 10,456 | $64.82 | $677.7K | 362.4K | Form 4 ↗ |
Trimarchi Thomas President and CFO | May 18, 2026 | Sale | 3,195 | $65.95 | $210.7K | 359.2K | Form 4 ↗ |
Kumar Neil Chief Executive Officer | May 16, 2026 | Tax Withhold | 36,236 | $66.13 | $2.40M | 269.4K | Form 4 ↗ |
Apuli Maricel Chief Accounting Officer | May 16, 2026 | Tax Withhold | 4,714 | $66.13 | $311.7K | 129.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BridgeBio Pharma, Inc. (BBIO) is primarily owned by institutional investors, who hold approximately 95.2% of total shares outstanding. Company insiders own approximately 13.69%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of BridgeBio Pharma, Inc. is VIKING GLOBAL INVESTORS LP, holding approximately 22.06 million shares — equal to 11.60% of outstanding shares — as of March 31, 2025.
A total of 349 institutional investors currently hold BBIO stock, with a combined institutional value of approximately $6.45 billion as of the most recent 13F filing period.
Frequently asked questions
BBIO ownershipBridgeBio Pharma, Inc. (BBIO) is primarily owned by institutional investors, who hold approximately 95.2% of shares. The largest shareholder is VIKING GLOBAL INVESTORS LP with a 11.60% stake. Company insiders hold 13.69%. Data sourced from SEC Form 13F as of March 31, 2025.